tailieunhanh - Báo cáo khoa học: Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action

The retroviral life cycle requires that significant amounts of RNA remain unspliced and perform several functions in the cytoplasm. Thus, the full-length RNA serves both the viral genetic material that will be encapsulated in viral particles and the mRNA encoding structural and enzymatic pro-teins required for viral replication. | ỊFEBS Journal MINIREVIEW Alternative splicing regulation of HIV-1 multiplication as a target for therapeutic action Jamal Tazi1 Nadia Bakkour1 Virginie Marchand2 Lilia Ayadi2 Amina Aboufirassi1 and Christiane Branlant2 1 Université Montpellier 2 Universite Montpellier 1 CNRS Institut de Génétique Moleculaire de Montpellier IGMM UMR5535 IFR122 Montpellier France 2 Universite Henri Poincare-Nancy I CNRS UMR 7214 Vandoeuvre-les-Nancy France Keywords alternative splicing HIV-1 hnRNP proteins retroviraltherapy SR proteins Correspondence J. Tazi Institut de Genetique Moleculaire de Montpellier IGMM 1919 route de Mende F-34293 Montpellier Cedex 5 France Fax 33 4 67 04 02 31 Tel 33 4 67 61 36 32 E-mail Received 28 August 2009 revised 31 October 2009 accepted 26 November 2009 The retroviral life cycle requires that significant amounts of RNA remain unspliced and perform several functions in the cytoplasm. Thus the fulllength RNA serves both the viral genetic material that will be encapsulated in viral particles and the mRNA encoding structural and enzymatic proteins required for viral replication. Simple retroviruses produce one singlespliced env RNA from the full-length precursor RNA whereas complex retroviruses such as HIV are characterized by the production of multiple-spliced RNA species. In this review we will summarize the current acknowledge about the HIV-1 alternative splicing mechanism and will describe how this malleable process can help further understanding of infection spread and dissemination through splicing regulation. Such studies coupled with the testing of splicing inhibitors should help the development of new therapeutic antiviral agents. doi Introduction The HIV AIDS epidemic is one of the primary health concerns worldwide 1 . Despite significant advances in anti-HIV chemotherapy the treatment and or prevention of the disease remains a largely unsolved problem. Current routine drug regimens .